DMPH.F Stock Overview

Manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. More details

DMPH.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	4/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 63% below our estimate of its fair value

Earnings are forecast to grow 10.5% per year

Earnings grew by 82.4% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Unstable dividend track record

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

Dermapharm Holding SE Competitors

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$1.7b

Organon

NYSE:OGN

US$2.9b

Prestige Consumer Healthcare

NYSE:PBH

US$4.0b

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$1.6b

Price History & Performance

Summary of share price highs, lows and changes for Dermapharm Holding
Historical stock prices
Current Share Price	€39.56
52 Week High	€39.56
52 Week Low	€39.56
Beta	1.34
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-7.32%

Recent updates

Shareholder Returns

	DMPH.F	US Pharmaceuticals	US Market
7D	0%	6.6%	-1.1%
1Y	n/a	-1.1%	5.9%

Return vs Industry: Insufficient data to determine how DMPH.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how DMPH.F performed against the US Market.

Price Volatility

Is DMPH.F's price volatile compared to industry and market?
DMPH.F volatility
DMPH.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	7.7%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	4.1%

Stable Share Price: DMPH.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine DMPH.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	3,610	Hans-Georg Feldmeier	ir.dermapharm.de

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.

Dermapharm Holding SE Fundamentals Summary

How do Dermapharm Holding's earnings and revenue compare to its market cap?
DMPH.F fundamental statistics
Market cap	US$2.24b
Earnings (TTM)	US$129.61m
Revenue (TTM)	US$1.36b

17.3x

P/E Ratio

1.6x

P/S Ratio

Is DMPH.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DMPH.F income statement (TTM)
Revenue	€1.20b
Cost of Revenue	€445.60m
Gross Profit	€749.85m
Other Expenses	€636.07m
Earnings	€113.79m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 15, 2025

Earnings per share (EPS)	2.11
Gross Margin	62.73%
Net Profit Margin	9.52%
Debt/Equity Ratio	159.9%

How did DMPH.F perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

43%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/18 08:00
End of Day Share Price	2025/03/27 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dermapharm Holding SE is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gerhard Orgonas	Berenberg
Daniel Wendorff	Commerzbank AG
Fabian Piasta	Jefferies LLC

Dermapharm Holding OTCPK:DMPH.F Stock Report